{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:26Z","timestamp":1791245186209,"version":"4.1.0"},"reference-count":99,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s10549-021-06280-x","type":"journal-article","created":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T07:02:49Z","timestamp":1623394969000},"page":"21-36","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies"],"prefix":"10.1007","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1996-6505","authenticated-orcid":false,"given":"Naomi","family":"Dempsey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitika","family":"Dabas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Kropotova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Lippman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanette H.","family":"Bishopric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,11]]},"reference":[{"key":"6280_CR1","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJCG Slamon","year":"1987","unstructured":"Slamon DJCG, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER2-2\/neu oncogene. Science 235:177\u2013182","journal-title":"Science"},{"issue":"15","key":"6280_CR2","first-page":"600","volume":"31","author":"NRB Katzorke","year":"2013","unstructured":"Katzorke NRB, Haeberle L et al (2013) Prognostic value of HER2 on breast cancer survival. J Clin Onc 31(15):600\u2013640","journal-title":"J Clin Onc"},{"issue":"33","key":"6280_CR3","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","volume":"32","author":"EA Perez","year":"2014","unstructured":"Perez EA, Romond EH, Suman VJ, Jeong JH, Sledge G, Geyer CE Jr et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744\u20133752","journal-title":"J Clin Oncol"},{"issue":"344","key":"6280_CR4","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJL-JB Slamon","year":"2001","unstructured":"Slamon DJL-JB, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2. N Eng J Med 344(344):783\u2013792","journal-title":"N Eng J Med"},{"issue":"24","key":"6280_CR5","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","volume":"60","author":"J Chen","year":"2012","unstructured":"Chen J, Long JB, Hurria A, Owusu C, Steingart RM, Gross CP (2012) Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 60(24):2504\u20132512","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"6280_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1056\/NEJM199103213241210","volume":"324","author":"JH Doroshow","year":"1991","unstructured":"Doroshow JH (1991) Doxorubicin-induced cardiac toxicity. N Engl J Med 324(12):843\u2013845","journal-title":"N Engl J Med"},{"issue":"4673","key":"6280_CR7","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1126\/science.6093249","volume":"226","author":"KMRT Tewey","year":"1984","unstructured":"Tewey KMRT, Yang L et al (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226(4673):466\u2013468","journal-title":"Science"},{"issue":"1","key":"6280_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","volume":"106","author":"GW De Keulenaer","year":"2010","unstructured":"De Keulenaer GW, Doggen K, Lemmens K (2010) The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 106(1):35\u201346","journal-title":"Circ Res"},{"issue":"22","key":"6280_CR9","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1056\/NEJMcibr1203156","volume":"367","author":"GM Cote","year":"2012","unstructured":"Cote GM, Sawyer DB, Chabner BA (2012) ERBB2 inhibition and heart failure. N Engl J Med 367(22):2150\u20132153","journal-title":"N Engl J Med"},{"key":"6280_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.toxlet.2018.01.001","volume":"285","author":"YK Kurokawa","year":"2018","unstructured":"Kurokawa YK, Shang MR, Yin RT, George SC (2018) Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes. Toxicol Lett 285:74\u201380","journal-title":"Toxicol Lett"},{"issue":"1","key":"6280_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s10549-012-2069-6","volume":"135","author":"S Jain","year":"2012","unstructured":"Jain S, Wei J, Mitrani LR, Bishopric NH (2012) Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival. Breast Cancer Res Treat 135(1):103\u2013114","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6280_CR12","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yjmcc.2004.11.005","volume":"38","author":"T Matsui","year":"2005","unstructured":"Matsui T, Rosenzweig A (2005) Convergent signal transduction pathways controlling cardiomyocyte survival and function: the role of PI 3-kinase and Akt. J Mol Cell Cardiol 38(1):63\u201371","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"6280_CR13","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2004.08.066","volume":"44","author":"LP Grazette","year":"2004","unstructured":"Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, Hajjar RJ et al (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44(11):2231\u20132238","journal-title":"J Am Coll Cardiol"},{"key":"6280_CR14","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/VHRM.S69641","volume":"11","author":"AKG Sandoo","year":"2015","unstructured":"Sandoo AKG, Carmichael AR (2015) Breast cancer therapy and cardiovascular risk: focus on trastuzumab. Vasc Health Risk Manag 11:223\u2013228","journal-title":"Vasc Health Risk Manag"},{"issue":"11","key":"6280_CR15","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1517\/14740338.2015.1089231","volume":"14","author":"HW Leung","year":"2015","unstructured":"Leung HW (2015) Trastuzumab-induced cardiotoxicity in elderly women with HER2-positive breast cancer: a meta-analysis of real-world data. Exp Opin Drug Safe. 14(11):1661\u20131671","journal-title":"Exp Opin Drug Safe."},{"issue":"44","key":"6280_CR16","doi-asserted-by":"publisher","first-page":"e5195","DOI":"10.1097\/MD.0000000000005195","volume":"95","author":"ZPR Jawa","year":"2016","unstructured":"Jawa ZPR, Garlie L et al (2016) Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine 95(44):e5195","journal-title":"Medicine"},{"issue":"4","key":"6280_CR17","first-page":"1717","volume":"33","author":"DRV Naumann","year":"2013","unstructured":"Naumann DRV, Margiotta C et al (2013) Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer. Anticancer Res 33(4):1717\u20131720","journal-title":"Anticancer Res"},{"key":"6280_CR18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1136\/heartjnl-2012-303151","volume":"99","author":"AME Farolfi","year":"2013","unstructured":"Farolfi AME, Aquilina M et al (2013) Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors. Heart 99:634\u2013639","journal-title":"Heart"},{"key":"6280_CR19","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","volume":"31","author":"MZN Chavez-MacGregor","year":"2013","unstructured":"Chavez-MacGregor MZN, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Onc 31:4222\u20134228","journal-title":"J Clin Onc"},{"issue":"1","key":"6280_CR20","doi-asserted-by":"publisher","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","volume":"3","author":"G Ezaz","year":"2014","unstructured":"Ezaz G, Long JB, Gross CP, Chen J (2014) Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc 3(1):e000472","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"6280_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1177\/1078155214567162","volume":"22","author":"MDB Gunaldi","year":"2015","unstructured":"Gunaldi MDB, Afsar C et al (2015) Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: an observational single-centre study. J Onc Pharm Pract 22(2):242\u2013247","journal-title":"J Onc Pharm Pract"},{"issue":"26","key":"6280_CR22","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1200\/JCO.2016.67.4846","volume":"34","author":"C LA Guenancia","year":"2016","unstructured":"LA Guenancia C, Cardinale D et al (2016) Obesity as a risk factor for anthracyclines and trastuzumab cardiotoxicity in breast cancer: a systematic review and meta-analysis. J Clin Oncol 34(26):3157\u20133165","journal-title":"J Clin Oncol"},{"issue":"9","key":"6280_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1007\/s12032-017-1018-y","volume":"34","author":"GHAS Tang","year":"2017","unstructured":"Tang GHAS, Sevick L, Yan AT, Brezden-Masley C (2017) Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single \u201creal-world\u201d setting. Med Oncol 34(9):154","journal-title":"Med Oncol"},{"issue":"8","key":"6280_CR24","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cardfail.2014.05.012","volume":"20","author":"KB Baron","year":"2014","unstructured":"Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, Tkaczuk KH et al (2014) Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population. J Card Fail 20(8):555\u2013559","journal-title":"J Card Fail"},{"issue":"4","key":"6280_CR25","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/annonc\/mdr348","volume":"23","author":"CCJ Serrano","year":"2012","unstructured":"Serrano CCJ, De Mattos-Arruda L et al (2012) Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Annals Onc 23(4):897\u2013902","journal-title":"Annals Onc"},{"issue":"31","key":"6280_CR26","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","volume":"30","author":"EHJJ Romond","year":"2012","unstructured":"Romond EHJJ, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive Human Epidermal. Gr J Clin Oncol 30(31):3792\u20133799","journal-title":"Gr J Clin Oncol"},{"issue":"14","key":"6280_CR27","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","volume":"365","author":"D Slamon","year":"2011","unstructured":"Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M et al (2011) Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 365(14):1273\u20131283","journal-title":"N Engl J Med"},{"issue":"12","key":"6280_CR28","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","volume":"19","author":"MS van Ramshorst","year":"2018","unstructured":"van Ramshorst MS, van der Voort A, van Werkhoven ED, Mandjes IA, Kemper I, Dezentj\u00e9 VO et al (2018) Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19(12):1630\u20131640","journal-title":"Lancet Oncol"},{"issue":"9","key":"6280_CR29","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24(9):2278\u20132284","journal-title":"Ann Oncol"},{"issue":"1","key":"6280_CR30","doi-asserted-by":"publisher","first-page":"5824","DOI":"10.1038\/s41467-020-19494-2","volume":"11","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz SA, Caswell-Jin JL, McNamara KL, Zoeller JJ, Bean GR, Dichmann R et al (2020) Pathologic and molecular responses to neoadjuvant trastuzumab and\/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun 11(1):5824","journal-title":"Nat Commun"},{"issue":"1","key":"6280_CR31","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SA Hurvitz","year":"2018","unstructured":"Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang C-S, Thompson AM et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19(1):115\u2013126","journal-title":"Lancet Oncol"},{"issue":"2","key":"6280_CR32","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1406281","volume":"372","author":"SM Tolaney","year":"2015","unstructured":"Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK et al (2015) Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372(2):134\u2013141","journal-title":"N Engl J Med"},{"key":"6280_CR33","volume-title":"A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT)","author":"SMT Tolaney","year":"2019","unstructured":"Tolaney SMT, Barrey L et al (2019) A randomized phase II study of adjuvant trastuzumab emtansine (T-DM1) vs paclitaxel (T) in combination with trastuzumab (H) for stage I HER2-positive breast cancer (BC) (ATEMPT). San Antonio Breast Cancer Symposium (SABCS), San Antonio, Texas"},{"issue":"3","key":"6280_CR34","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3747\/co.24.3349","volume":"24","author":"MJC Rushton","year":"2017","unstructured":"Rushton MJC, Dent S (2017) Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. Curr Onc 24(3):176\u2013180","journal-title":"Curr Onc"},{"issue":"48","key":"6280_CR35","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1093\/eurheartj\/ehz460","volume":"40","author":"H Abdel-Qadir","year":"2019","unstructured":"Abdel-Qadir H, Thavendiranathan P, Austin PC, Lee DS, Amir E, Tu JV et al (2019) Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J 40(48):3913\u20133920","journal-title":"Eur Heart J"},{"issue":"8","key":"6280_CR36","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jcmg.2018.06.004","volume":"11","author":"JHTR Jordan","year":"2018","unstructured":"Jordan JHTR, Vasu S, Hundley WG (2018) Cardiovascular magnetic resonance in the oncology patient. JACC Cardiovasc Imag 11(8):1150\u20131172","journal-title":"JACC Cardiovasc Imag"},{"issue":"10","key":"6280_CR37","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/ehjci\/jeu192","volume":"15","author":"JCGM Plana","year":"2014","unstructured":"Plana JCGM, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Euro Heart J Cardioasc Imag 15(10):1063\u20131093","journal-title":"Euro Heart J Cardioasc Imag"},{"issue":"12","key":"6280_CR38","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1093\/eurheartj\/ehz550","volume":"41","author":"GJ Wehner","year":"2020","unstructured":"Wehner GJ, Jing L, Haggerty CM, Suever JD, Leader JB, Hartzel DN et al (2020) Routinely reported ejection fraction and mortality in clinical practice: where does the nadir of risk lie? Eur Heart J 41(12):1249\u20131257","journal-title":"Eur Heart J"},{"issue":"1","key":"6280_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L et al (2015) Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28(1):1-39.e14","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"6280_CR40","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12968-017-0348-4","volume":"19","author":"H Huang","year":"2017","unstructured":"Huang H, Nijjar PS, Misialek JR, Blaes A, Derrico NP, Kazmirczak F et al (2017) Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: comparison with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 19(1):34","journal-title":"J Cardiovasc Magn Reson"},{"key":"6280_CR41","doi-asserted-by":"crossref","unstructured":"Manrique CR, Tiwari N, Plana JC, Garcia MJ (2017) diagnostic strategies for early recognition of cancer therapeutics\u2013related cardiac dysfunction. Clin Med Insights Cardiol 11: eCollection","DOI":"10.1177\/1179546817697983"},{"issue":"5","key":"6280_CR42","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","volume":"26","author":"KNT Negishi","year":"2013","unstructured":"Negishi KNT, Hare JL et al (2013) Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echo 26(5):493\u2013498","journal-title":"J Am Soc Echo"},{"issue":"4","key":"6280_CR43","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Negishi T, Somerset E, Negishi K, Penicka M, Lemieux J et al (2021) Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 77(4):392\u2013401","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6280_CR44","doi-asserted-by":"publisher","first-page":"002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","volume":"9","author":"MWHC Bloom","year":"2016","unstructured":"Bloom MWHC, Cardinale D et al (2016) Cancer therapy-related cardiac dysfunction and heart failure: part 1: definitions, pathophysiology, risk factors, and imaging. Circ Heart Fail 9(1):002661","journal-title":"Circ Heart Fail"},{"issue":"6","key":"6280_CR45","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1161\/CIRCIMAGING.113.000899","volume":"6","author":"PWB Thavendiranthan","year":"2013","unstructured":"Thavendiranthan PWB, Flamm SD et al (2013) Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imag 6(6):1080\u20131091","journal-title":"Circ Cardiovasc Imag"},{"issue":"S1","key":"6280_CR46","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1532-429X-11-S1-P18","volume":"11","author":"GKP Smith","year":"2009","unstructured":"Smith GKP, Carpenter JP et al (2009) Cardiovascular magnetic resonance imaging in early anthracycline cardiotoxicity. J Cardiovasc Magn Reson 11(S1):18","journal-title":"J Cardiovasc Magn Reson"},{"issue":"7","key":"6280_CR47","doi-asserted-by":"publisher","first-page":"e004560","DOI":"10.1161\/CIRCHEARTFAILURE.117.004560","volume":"11","author":"JH Jordan","year":"2018","unstructured":"Jordan JH, Castellino SM, Mel\u00e9ndez GC, Klepin HD, Ellis LR, Lamar Z et al (2018) Left ventricular mass change after anthracycline chemotherapy. Circ Heart Fail 11(7):e004560","journal-title":"Circ Heart Fail"},{"issue":"1","key":"6280_CR48","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1532-429X-10-5","volume":"10","author":"N Fallah-Rad","year":"2008","unstructured":"Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS (2008) Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. J Cardiovasc Magn Reson 10(1):5","journal-title":"J Cardiovasc Magn Reson"},{"issue":"8","key":"6280_CR49","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","volume":"35","author":"DST Zardavas","year":"2017","unstructured":"Zardavas DST, Van Veldhuisen DJ et al (2017) Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safey of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a herceptin adjuvant study car. J Clin Oncol 35(8):878\u2013884","journal-title":"J Clin Oncol"},{"issue":"25","key":"6280_CR50","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"DCA Cardinale","year":"2010","unstructured":"Cardinale DCA, Torrisi R et al (2010) Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol 28(25):3910\u20133916","journal-title":"J Clin Oncol"},{"issue":"9","key":"6280_CR51","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","volume":"107","author":"HSI Sawaya","year":"2011","unstructured":"Sawaya HSI, Plana JC et al (2011) Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol 107(9):1375\u20131380","journal-title":"Am J Cardiol"},{"key":"6280_CR52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1185\/03007995.2015.1005834","volume":"3","author":"MAAS Sendur","year":"2015","unstructured":"Sendur MAAS, Ozdemir N et al (2015) Comparison of long-term cardiac effects of 9-and 52-week trastuzumab in HER2-positive early breast cancer. Curr Med Res Opin 3:547\u2013556","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"6280_CR53","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1373\/clinchem.2015.241232","volume":"61","author":"MHV Putt","year":"2015","unstructured":"Putt MHV, Januzzi JL et al (2015) Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem 61(9):1164\u20131172","journal-title":"Clin Chem"},{"issue":"3","key":"6280_CR54","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10549-017-4628-3","volume":"168","author":"NBI Ponde","year":"2018","unstructured":"Ponde NBI, Lambertini M et al (2018) Cardiac biomarkers for early detection and prediction of trastuzumab and\/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1\u201306). Breast Cancer Res Treat 168(3):631\u2013638","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"6280_CR55","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1158\/1078-0432.CCR-10-1359","volume":"17","author":"PG Morris","year":"2011","unstructured":"Morris PG, Steingart R et al (2011) Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib. Clin Cancer Res 17(10):3490\u20133499","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6280_CR56","first-page":"40","volume":"107","author":"EJB Matos","year":"2016","unstructured":"Matos EJB, Blagus R et al (2016) A prospective cohort study on cardiotoxicity of adjuvant trastuzumab in breast cancer patients. Arq Bras Cardiol 107(1):40\u201347","journal-title":"Arq Bras Cardiol"},{"issue":"22","key":"6280_CR57","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","volume":"57","author":"NWJ Fallah-Rad","year":"2011","unstructured":"Fallah-Rad NWJ, Wassef A et al (2011) Utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuv. J Am Coll Cardiol 57(22):2263\u20132270","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"6280_CR58","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10928-018-9579-8","volume":"45","author":"AHM de Vries Schultink","year":"2018","unstructured":"de Vries Schultink AHM, Boekhout AH, Gietema JA, Burylo AM, Dorlo TPC, van Hasselt JGC et al (2018) Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens. J Pharmacokinet Pharmacodyn 45(3):431\u2013442","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"6280_CR59","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0735-1097(00)00748-8","volume":"36","author":"DSM Cardinale","year":"2000","unstructured":"Cardinale DSM, Martinoni A et al (2000) Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 36(2):517\u2013522","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"6280_CR60","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","volume":"109","author":"DSM Cardinale","year":"2004","unstructured":"Cardinale DSM, Colombo A et al (2004) Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulat 109(22):2749\u20132754","journal-title":"Circulat"},{"issue":"2","key":"6280_CR61","doi-asserted-by":"publisher","first-page":"e014708","DOI":"10.1161\/JAHA.119.014708","volume":"9","author":"BG Demissei","year":"2020","unstructured":"Demissei BG, Hubbard RA, Zhang L, Smith AM, Sheline K, McDonald C et al (2020) Changes in cardiovascular biomarkers with breast cancer therapy and associations with cardiac dysfunction. J Am Heart Assoc 9(2):e014708","journal-title":"J Am Heart Assoc"},{"issue":"2","key":"6280_CR62","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1743-7563.2012.01588.x","volume":"9","author":"AVY Kittiwarawut","year":"2013","unstructured":"Kittiwarawut AVY, Tanasanvimon S et al (2013) Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction. Asia Pac J Clin Oncol 9(2):155\u2013161","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"6280_CR63","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.cardfail.2016.04.003","volume":"22","author":"DJ Lenihan","year":"2016","unstructured":"Lenihan DJ, Massey M et al (2016) The utility of point of care biomarkers to detect cardiotoxicity during anthracycline chemotherapy: a feasibility study. J Card Fail 22(6):433\u2013438","journal-title":"J Card Fail"},{"issue":"11","key":"6280_CR64","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/bjc.2011.439","volume":"105","author":"SFS Romano","year":"2011","unstructured":"Romano SFS, Ricevuto E et al (2011) Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer 105(11):1663\u20131668","journal-title":"Br J Cancer"},{"issue":"8","key":"6280_CR65","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1373\/clinchem.2005.050153","volume":"51","author":"MT Sandri","year":"2005","unstructured":"Sandri MT, Cardinale D et al (2005) N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction. Clin Chem 51(8):1405\u20131410","journal-title":"Clin Chem"},{"key":"6280_CR66","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.breast.2017.10.010","volume":"37","author":"DM Gujral","year":"2018","unstructured":"Gujral DM, Bhattacharyya S (2018) Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction and heart failure during anthracycline chemotherapy trastuzumab. Breast 37:64\u201371","journal-title":"Breast"},{"issue":"8","key":"6280_CR67","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"EMJ Pituskin","year":"2016","unstructured":"Pituskin EMJ, Koshman S et al (2016) Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101\u2013Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol 35(8):870\u2013877","journal-title":"J Clin Oncol"},{"issue":"22","key":"6280_CR68","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"MKJ Guglin","year":"2019","unstructured":"Guglin MKJ, Tamura R et al (2019) Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol 73(22):2859\u20132868","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"6280_CR69","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"GHS Gulati","year":"2016","unstructured":"Gulati GHS, Ree AH et al (2016) Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J 37(21):1671\u20131680","journal-title":"Eur Heart J"},{"issue":"2","key":"6280_CR70","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cjca.2018.11.028","volume":"35","author":"O Calvillo-Arguelles","year":"2019","unstructured":"Calvillo-Arguelles O, Michalowaska M et al (2019) Cardioprotective effect of statins in patients with her2-positive breast cancer receiving trastuzumab therapy. Can J Cardiol 35(2):153\u2013159","journal-title":"Can J Cardiol"},{"issue":"8","key":"6280_CR71","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Kerklaan BM et al (2016) Angiotensin II\u2013receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol 2(8):1030\u20131037","journal-title":"JAMA Oncol"},{"key":"6280_CR72","doi-asserted-by":"publisher","first-page":"7820","DOI":"10.1200\/JCO.2005.13.300","volume":"23","author":"MSVM Ewer","year":"2005","unstructured":"Ewer MSVM, Durand JB et al (2005) Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 23:7820\u20137826","journal-title":"J Clin Oncol"},{"issue":"3","key":"6280_CR73","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"F Lynce","year":"2019","unstructured":"Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL et al (2019) Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat 175(3):595\u2013603","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"6280_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2019.06.004","volume":"1","author":"DP Leong","year":"2019","unstructured":"Leong DP, Cosman T, Alhussein MM, Tyagi NK, Karampatos S, Barron CC et al (2019) Safety of continuing trastuzumab despite mild cardiotoxicity. JACC Cardio Oncol 1(1):1\u201310","journal-title":"JACC Cardio Oncol"},{"issue":"6","key":"6280_CR75","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CWJM Yancy","year":"2017","unstructured":"Yancy CWJM, Bozkurt B et al (2017) 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the american college of cardiology\/american heart association task force on clinical practice guidelines and the heart failure society of amer. J Am Coll Cardiol 70(6):776\u2013803","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"6280_CR76","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"GPM Von Minckwitz","year":"2017","unstructured":"Von Minckwitz GPM, de Azambuja E et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Eng J Med 377(2):122\u2013131","journal-title":"N Eng J Med"},{"issue":"6","key":"6280_CR77","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S1470-2045(16)00163-7","volume":"17","author":"LPT Gianni","year":"2016","unstructured":"Gianni LPT, Im YH et al (2016) 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol 17(6):791\u2013800","journal-title":"Lancet Oncol"},{"key":"6280_CR78","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa1113216","volume":"366","author":"JCJ Baselga","year":"2012","unstructured":"Baselga JCJ, Kim SB et al (2012) CLEOPATRA study group: pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109\u2013119","journal-title":"N Engl J Med"},{"issue":"7","key":"6280_CR79","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IEKS Krop","year":"2014","unstructured":"Krop IEKS, Gonzalez-Martin A et al (2014) Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol 15(7):689\u2013699","journal-title":"Lancet Oncol"},{"issue":"19","key":"6280_CR80","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"SMD Verma","year":"2012","unstructured":"Verma SMD, Gianni L et al (2012) Trastuzumab emtansine for HER2-positive advanced breast cancer. N Eng J Med 367(19):1783\u20131791","journal-title":"N Eng J Med"},{"issue":"1","key":"6280_CR81","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","volume":"19","author":"SAMM Hurvitz","year":"2018","unstructured":"Hurvitz SAMM, Symmans WF et al (2018) Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 19(1):115\u2013126","journal-title":"Lancet Oncol"},{"issue":"2","key":"6280_CR82","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EABC Perez","year":"2017","unstructured":"Perez EABC, Eiermann W et al (2017) Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the Phase III MARIANNE study. J Clin Oncol 35(2):141\u2013148","journal-title":"J Clin Oncol"},{"issue":"7","key":"6280_CR83","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"GHC Von Minckwitz","year":"2019","unstructured":"Von Minckwitz GHC, Mano MS et al (2019) Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Eng J Med 380(7):617\u2013628","journal-title":"N Eng J Med"},{"issue":"6","key":"6280_CR84","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0025-6196(11)60896-3","volume":"83","author":"EAKM Perez","year":"2008","unstructured":"Perez EAKM, Byrne J et al (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 83(6):679\u2013686","journal-title":"Mayo Clin Proc"},{"issue":"26","key":"6280_CR85","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","volume":"355","author":"CEFJ Geyer","year":"2008","unstructured":"Geyer CEFJ, Lindquist D et al (2008) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Eng J Med 355(26):2733\u20132743","journal-title":"N Eng J Med"},{"issue":"12","key":"6280_CR86","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jamaoncol.2016.0237","volume":"2","author":"ACR Awada","year":"2016","unstructured":"Awada ACR, Inoue K et al (2016) Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic ERBB2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol 2(12):1557\u20131564","journal-title":"JAMA Oncol"},{"issue":"3","key":"6280_CR87","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","volume":"17","author":"ADS Chan","year":"2016","unstructured":"Chan ADS, Holmes FA et al (2016) Neratinib after trastuzumab- based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 17(3):367\u2013377","journal-title":"Lancet Oncol"},{"issue":"7","key":"6280_CR88","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","volume":"19","author":"RBV Murthy","year":"2018","unstructured":"Murthy RBV, Conlin A et al (2018) Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol 19(7):880\u2013888","journal-title":"Lancet Oncol"},{"key":"6280_CR89","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RLS Murthy","year":"2020","unstructured":"Murthy RLS, Okines A et al (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Eng J Med 382:597\u2013609","journal-title":"N Eng J Med"},{"issue":"4","key":"6280_CR90","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1093\/annonc\/mdx002","volume":"28","author":"YJGG Bang","year":"2017","unstructured":"Bang YJGG, Im S (2017) First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Annals Onc 28(4):855\u2013861","journal-title":"Annals Onc"},{"issue":"15","key":"6280_CR91","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2019.37.15_suppl.1000","volume":"37","author":"HWG Rugo","year":"2019","unstructured":"Rugo HWG, Seock-Ah I et al (2019) SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). J Clin Onc 37(15):1000","journal-title":"J Clin Onc"},{"key":"6280_CR92","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1056\/NEJMoa1914510","volume":"382","author":"SSC Modi","year":"2020","unstructured":"Modi SSC, Yamashita T et al (2020) Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Eng J Med 382:610\u2013621","journal-title":"N Eng J Med"},{"issue":"2","key":"6280_CR93","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/bcr3621","volume":"16","author":"MJH Barok","year":"2014","unstructured":"Barok MJH, Isola J (2014) Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res 16(2):209","journal-title":"Breast Cancer Res"},{"issue":"6","key":"6280_CR94","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J et al (2017) Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 18(6):732\u2013742","journal-title":"Lancet Oncol"},{"issue":"10","key":"6280_CR95","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/s41416-020-0786-x","volume":"122","author":"D Eiger","year":"2020","unstructured":"Eiger D, Pond\u00e9 NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS et al (2020) Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and\/or trastuzumab treatment optimization trial. Br J Cancer 122(10):1453\u20131460","journal-title":"Br J Cancer"},{"issue":"12","key":"6280_CR96","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","volume":"18","author":"M Martin","year":"2017","unstructured":"Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H et al (2017) Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 18(12):1688\u20131700","journal-title":"Lancet Oncol"},{"issue":"8","key":"6280_CR97","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, Carver J, Constine LS, Denduluri N et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: american society of clinical oncology clinical practice guideline. J Clin Oncol 35(8):893\u2013911","journal-title":"J Clin Oncol"},{"issue":"9","key":"6280_CR98","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1097\/COC.0000000000000389","volume":"41","author":"S Wittayanukorn","year":"2018","unstructured":"Wittayanukorn S, Qian J, Westrick SC, Billor N, Johnson B, Hansen RA (2018) Prevention of trastuzumab and anthracycline-induced cardiotoxicity using angiotensin-converting enzyme inhibitors or \u03b2-blockers in older adults with breast cancer. Am J Clin Oncol 41(9):909\u2013918","journal-title":"Am J Clin Oncol"},{"issue":"2","key":"6280_CR99","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A et al (2020) Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. ESMO Annals Oncol 31(2):171","journal-title":"ESMO Annals Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06280-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06280-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06280-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T16:09:40Z","timestamp":1675440580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06280-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,11]]},"references-count":99,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6280"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06280-x","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,11]]},"assertion":[{"value":"16 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Marc Lippman as a possible COI as a director of Seattle Genetics, the manufacturer of Tucatinib.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}